Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines

Cancer Cell International

Vichai Reutrakul²  Banchob Sripa⁴  Sakawrat Kanthawong⁵  Natthinee Anantachoke¹  Chariya Chomvarin³  Wareeporn Wattanawongdon³  Chariya Hahnvajanawong³ 

[1] Department of Pharmacognosy, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand;Department of Chemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand;Liver Fluke and Cholangiocarcinoma Research Center, Khon Kaen University, Khon Kaen 40002, Thailand;Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand;Department of Microbiology, Center of Excellence for Innovation in Chemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand

关键词: Human cholangiocarcinoma cell lines;    Apoptosis;    Synergistic effect;    Doxorubicin;    Forbesione;    Isomorellin;   

Others  :  1121645
DOI  :  10.1186/1475-2867-14-68

 received in 2013-08-02, accepted in 2014-05-22,  发布年份 2014

【 摘 要 】

Background

Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural compounds represent a promising strategy. In our previous studies, isomorellin and forbesione, caged xanthones isolated from Garcinia hanburyi, were found to induce cell cycle arrest and apoptosis in CCA cell lines. The subject of our inquiry is the synergistic effect(s) of these caged xanthones with doxorubicin on growth inhibition and apoptosis induction in human CCA cell lines.

Methods

KKU-100, KKU-M139 and KKU-M156 cell lines and Chang cells were treated with either isomorellin or forbesione alone or in combination with doxorubicin. Cell viability was determined using the sulforhodamine B assay. The combined effects of plant compounds with doxorubicin were analyzed using the isobologram and combination index method of Chou-Talalay. Apoptosis was determined by ethidium bromide/acridine orange staining. Protein expressions were determined by Western blot analysis.

Results

Isomorellin or forbesione alone inhibited the growth of these CCA cell lines in a dose-dependent manner and showed selective cytotoxicity against CCA cells but not against Chang cells. Isomorellin/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-M139 and KKU-M156 cells, while the forbesione/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-100 and KKU-M139 cells. The percentages of apoptotic cells were significantly higher in the combined treatments than in the respective single drug treatments. The combined treatments strongly enhanced the expression of Bax/Bcl-2, activated caspase-9 and caspase-3, while suppressing the expression of survivin, procaspase-9 and procaspase-3, compared with single drug treatments. The degree of suppression of NF-κB activation mediated by a decrease in the expression of NF-κB/p65, a reduction of the pIκB-α level and an increase in the IκB-α protein level, was significantly higher in the combined treatment groups than in the single drug treatment groups. The degree of suppression of MRP1 protein expression was also significantly higher in the combined treatment than in the single drug treatment groups.

Conclusion

The combinations of isomorellin/doxorubicin and forbesione/doxorubicin showed significant synergistic effects on the growth inhibition and apoptosis induction in KKU-M156 and KKU-100 cells. Caged xanthones may be useful adjunct treatments with chemotherapy for Opisthorchis viverrini (OV)-associated CCA.

【 授权许可】

   
2014 Hahnvajanawong et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Welzel TM, McGlynn KA, Hsing AW, O’Brien TR, Pfeiffer RM: Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006, 98:873-5.
• [2]West J, Wood H, Logan RF, Quinn M, Aithal GP: Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001. Br J Cancer 2006, 94:1751-8.
• [3]Olnes MJ, Erlich R: A review and update on cholangiocarcinoma. Oncology 2004, 66:167-79.
• [4]Thongprasert S: The role of chemotherapy in cholangiocarcinoma. Ann Oncol 2005, 16(Suppl 2):ii93-6.
• [5]Raghavan D, Koczwara B, Javle M: Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Cancer 1997, 33:566-74.
• [6]Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979, 91:710-7.
• [7]Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70.
• [8]Okaro AC, Deery AR, Hutchins RR, Davidson BR: The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium. J Clin Pathol 2001, 54:927-32.
• [9]Harnois DM, Que FG, Celli A, LaRusso NF, Gores GJ: Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line. Hepatology 1997, 26:884-90.
• [10]Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, Kaufmann SH, Gores GJ: Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 2004, 64:3517-24.
• [11]Namwat N, Amimanan P, Loilome W, Jearanaikoon P, Sripa B, Bhudhisawasdi V, Tassaneeyakul W: Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell lines. Chemotherapy 2008, 54:343-51.
• [12]Pinlaor S, Hiraku Y, Yongvanit P, Tada-Oikawa S, Ma N, Pinlaor P, Sithithaworn P, Sripa B, Murata M, Oikawa S, Kawanishi S: iNOS-dependent DNA damage via NF-kappaB expression in hamsters infected with Opisthorchis viverrini and its suppression by the antihelminthic drug praziquantel. Int J Cancer 2006, 119:1067-72.
• [13]Borst P, Evers R, Kool M, Wijnholds J: A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000, 92:1295-302.
• [14]Tepsiri N, Chaturat L, Sripa B, Namwat W, Wongkham S, Bhudhisawasdi V, Tassaneeyakul W: Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol 2005, 11:2748-53.
• [15]Courtois A, Payen L, Lagadic D, Guillouzo A, Fardel O: Evidence for a multidrug resistance-associated protein 1 (MRP1)-related transport system in cultured rat liver biliary epithelial cells. Life Sci 1999, 64:763-74.
• [16]Wang T, Wei J, Qian X, Ding Y, Yu L, Liu B: Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett 2008, 262:214-22.
• [17]Wang J, Liu W, Zhao Q, Qi Q, Lu N, Yang Y, Nei FF, Rong JJ, You QD, Guo QL: Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. Toxicology 2009, 256:135-40.
• [18]Han QB, Xu HX: Caged Garcinia xanthones: development since 1937. Curr Med Chem 2009, 16:3775-96.
• [19]Zhao L, Guo QL, You QD, Wu ZQ, Gu HY: Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells. Biol Pharm Bull 2004, 27:998-1003.
• [20]Qiang L, Yang Y, You QD, Ma YJ, Yang L, Nie FF, Gu HY, Zhao L, Lu N, Qi Q, Liu W, Wang XT, Guo QL: Inhibition of glioblastoma growth and angiogenesis by gambogic acid: an in vitro and in vivo study. Biomed Pharmacol 2008, 75:1083-92.
• [21]Guo QL, Lin SS, You QD, Gu HY, Yu J, Zhao L, Qi Q, Liang F, Tan Z, Wang XT: Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC-7721 cells. Life Sci 2006, 78:1238-45.
• [22]Yu J, Guo QL, You QD, Zhao L, Gu HY, Yang Y, Zhang HW, Tan Z, Wang X: Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis 2007, 28:632-8.
• [23]Qi Q, Gu HY, Yang Y, Lu N, Zhao J, Liu W, Ling H, You QD, Wang XT, Guo QL: Involvement of matrix metalloproteinase 2 and 9 in gambogic acid induced suppression of MDA-MB-435 human breast carcinoma cell lung metastasis. J Mol Med (Berl) 2008, 86:1367-77.
• [24]Qin YX, Meng LH, Hu CX, Duan WH, Zuo ZL, Lin LP, Zhang XW, Ding J: Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain. Mol Cancer Ther 2007, 6:2429-40.
• [25]Toledano MB, Leonard WJ: Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci U S A 1991, 88:4328-32.
• [26]Yang Y, Yang L, You QD, Nie FF, Gu HY, Zhao L, Wang XT, Guo QL: Differential apoptotic induction of gambogic acid, a novel anticancer natural product, on hepatoma cells and normal hepatocytes. Cancer Lett 2007, 256:259-66.
• [27]Guo QL, Qi Q, You QD, Gu HY, Zhao L, Wu ZQ: Toxicological studies of gambogic acid and its potential targets in experimental animals. Basic Clin Pharmacol Toxicol 2006, 99:178-84.
• [28]Zhou ZT, Wang JW: Phase I human tolerability trial of gambogic acid. Chin J New Drugs 2007, 16:79-82.
• [29]Hahnvajanawong C, Boonyanugomol W, Nasomyon T, Loilome W, Namwat N, Anantachoke N, Tassaneeyakul W, Sripa B, Namwat W, Reutrakul V: Apoptotic activity of caged xanthones from Garcinia hanburyi in cholangiocarcinoma cell lines. World J Gastroenterol 2010, 16:2235-43.
• [30]Hahnvajanawong C, Ketnimit S, Pattanapanyasat K, Anantachoke N, Sripa B, Pinmai K, Seubwai W, Reutrakul V: Involvement of p53 and nuclear factor-kappaB signaling pathway for the induction of G1-phase cell cycle arrest of cholangiocarcinoma cell lines by isomorellin. Biol Pharm Bull 2012, 35:1914-25.
• [31]Chou TC, Motzer RJ, Tong Y, Bosl GJ: Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994, 86:1517-24.
• [32]Chou TC, Talalay P: Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 1983, 4:450-4.
• [33]Perkins ND: The Rel/NF-kappa B family: friend and foe. Trends Biochem Sci 2000, 25:434-40.
• [34]Yang PM, Huang WC, Lin YC, Huang WY, Wu HA, Chen WL, Chang YF, Chou CW, Tzeng CC, Chen YL, Chen CC: Loss of IKKbeta activity increases p53 stability and p21 expression leading to cell cycle arrest and apoptosis. J Cell Mol Med 2010, 14:687-98.
• [35]Huang H, Chen D, Li S, Li X, Liu N, Lu X, Liu S, Zhao K, Zhao C, Guo H, Yang C, Zhou P, Dong X, Zhang C, Guanmei , Dou QP, Liu J: Gambogic acid enhances proteasome inhibitor-induced anticancer activity. Cancer Lett 2011, 301:221-8.
• [36]Reutrakul V, Anantachoke N, Pohmakotr M, Jaipetch T, Sophasan S, Yoosook C, Kasisit J, Napaswat C, Santisuk T, Tuchinda P: Cytotoxic and anti-HIV-1 caged xanthones from the resin and fruits of Garcinia hanburyi. Planta Med 2007, 73:33-40.
• [37]Wu ZQ, Guo QL, You QD, Zhao L, Gu HY: Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull 2004, 27:1769-74.
• [38]Anuszewska E, Chlopkiewicz B, Gruber B, Marczewska J, Priebe W, Skurzak H: Estimation of DNA damage and cytotoxicity of anthracycline analogs in human melanoma cells on early and late passages. Acta Pol Pharm 2006, 63(4):321-4.
• [39]Chen ST, Pan TL, Tsai YC, Huang CM: Proteomics reveals protein profile changes in doxorubicin-treated MCF-7 human breast cancer cells. Cancer Lett 2002, 181:95-107.
• [40]Hortobagyi GN: Progress in systemic chemotherapy of primary breast cancer: an overview. J Natl Cancer Inst Monogr 2001, 30:72-9.
• [41]Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R: Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clin Cancer Res 2002, 8:3512-9.
• [42]Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, Spalla C: Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng 1969, 11:1101-10.
• [43]Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-27.
• [44]Kaufmann SH, Vaux DL: Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003, 22:7414-30.
• [45]Green DR, Reed JC: Mitochondria and apoptosis. Science 1998, 281:1309-12.
• [46]Bras M, Queenan B, Susin SA: Programmed cell death via mitochondria: different modes of dying. Biochemistry (Mosc) 2005, 70:231-9.
• [47]Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK, Oh BH: An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and −7. Biochemistry 2001, 40:1117-23.
• [48]Ghosh S, Karin M: Missing pieces in the NF-kappaB puzzle. Cell 2002, 109(Suppl):S81-96.
• [49]Cusack JC, Liu R, Baldwin AS: NF- kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF- kappa B. Drug Resist Updat 1999, 2:271-3.
• [50]Naus P, Henson R, Bleeker G, Wehbe H, Meng F, Patel T: Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways. J Hepatol 2007, 46:222-9.
• [51]Quan F, Pan C, Ma Q, Zhang S, Yan L: Reversal effect of resveratrol on multidrug resistance in KBv200 cell line. Biomed Pharmacother 2008, 62:622-9.
• [52]Jinawath N, Chamgramol Y, Furukawa Y, Obama K, Tsunoda T, Sripa B, Pairojkul C, Nakamura Y: Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology 2006, 44(4):1025-38.
• [53]Chan-On W, Nairismagi ML, Ong CK, Lim WK, Dima S, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL, Ooi L, Chung A, Chow P, Cheow PC, Lee SY, Choo SP, Tan IB, Duda D, Nastase A, Myint SS, Wong BH, Gan A, Rajasegaran V, Ng CC, Nagarajan S, Jusakul A, Zhang S, Vohra P, Yu W, Huang D: Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet 2013, 45(12):1474-8.
• [54]Sripa B, Leungwattanawanit S, Nitta T, Wongkham C, Bhudhisawasdi V, Puapairoj A, Sripa C, Miwa M: Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World J Gastroenterol 2005, 11:3392-7.
• [55]Pinmai K, Chunlaratthanabhorn S, Ngamkitidechakul C, Soonthornchareon N, Hahnvajanawong C: Synergistic growth inhibitory effects of Phyllanthus emblica and Terminalia bellerica extracts with conventional cytotoxic agents: doxorubicin and cisplatin against human hepatocellular carcinoma and lung cancer cells. World J Gastroenterol 2008, 14:1491-7.
• [56]Ribble D, Goldstein NB, Norris DA, Shellman YG: A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol 2005, 5:12. BioMed Central Full Text